1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
EQL Pharma AB

EQL Pharma AB

19.92
SEK
-0.08
(-0.40%)
-0.03EPS
699.85MMarket Cap
Nov 05Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1.64
1.08
1.16
1.11
1.31
1.71
2.48
6.16
14.1
8.94
9.09
12.85
14.65
15.41
Basic EPS, GAAP
-0.57
-0.54
0.16
0.14
-0.02
-0.05
0.09
0.36
1.09
1.06
0.78
1.48
0.42
-0.03
Free Cash Flow per Basic Share
-0.75
-0.85
-0.24
-0.24
-0.71
-0.35
-0.38
0.15
0.68
0.24
-2.67
-9.31
-1.32
-1.96
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.46
0.36
1.86
2.24
2.13
2.69
2.78
3.14
4.25
5.32
6.12
7.61
9.04
8.48
Tangible Book Value per Share
-0.13
-0.19
1.26
1.43
0.74
1.03
0.64
-0.32
0.46
1.36
0.15
-6.24
-5.89
-6.75
Basic Weighted Avg Shares
14
16
23
25
26
29
29
29
29
29
29
29
30
29
Sales/Revenue/Turnover
22
18
27
28
34
50
72
179
410
260
264
374
433
453
Operating Margin (%)
-19.52
-43.41
15.52
12.59
-1.52
-2.86
4.38
6.25
9.41
15.82
12.21
17.76
10.95
6.95
Depreciation Expense
1
1
1
2
2
5
4
17
10
14
9
13
23
- -
Net Income, GAAP
-8
-9
4
4
-1
-2
3
10
32
31
23
43
13
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
0.62
0.53
12.28
20.65
20.62
20.66
31.13
163.34
Profit Margin (%)
-34.77
-49.95
13.85
12.56
-1.52
-3.04
3.76
5.79
7.7
11.9
8.59
11.55
2.9
-0.19
Working Capital
1
-1
32
36
19
29
18
3
25
50
36
179
194
165
LT Debt
1
1
- -
- -
- -
- -
- -
17
11
2
16
341
345
346
Total Equity
7
6
47
57
57
78
81
91
124
155
178
221
267
250
Return on Invested Capital (%)
- -
- -
15.23
6.78
- -
- -
3.93
8.73
17.9
15.4
9.83
10.82
4.69
-2.81
Return on Capital (%)
- -
- -
15.23
6.78
- -
- -
3.94
8.84
18.02
15.58
10.5
10.86
4.38
-2.83
Return on Common Equity (%)
-172.6
-136.84
13.87
6.77
-0.91
-2.24
3.4
12.04
29.37
22.22
13.66
21.63
5.14
-0.36

Capital Structure

SEK

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
129
114
139
LT Borrowings
341
342
- -
LT Finance Leases
- -
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
1,707
1,606
700

Working Capital

SEK

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
377
404
364
Cash, Cash Equivalents & STI
73
87
61
Accounts Receivable, Net
81
93
82
Inventories
197
201
199
Total Current Liabilities
174
210
200
Payables & Accruals
- -
- -
- -
ST Debt
129
114
139
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.47%
24.15%
20.82%
Free Cash Flow
-71.97%
-150.64%
-85.63%
Net Income, GAAP
27.26%
38.95%
-70.93%
Sales/Revenue/Turnover
41.64%
30.2%
15.83%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
83
85
92
113
374
2026
107
- -
119
120
433
2027
107
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.36
0.33
0.35
0.45
1.48
2026
0.34
- -
0.33
-0.13
0.42
2027
-0.57
- -
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Axel Schörling
Full Time Employees
23
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
Lund Sweden
IPO Date
Oct 25, 2013
Website
eqlpharma.com
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
EQL Pharma AB is a Sweden-based specialty pharmaceutical company engaged in the development, in-licensing, registration, and commercialization of niche generic pharmaceuticals, prescription medications, and hospital-use specialty therapies. The company focuses on cost-effective medicines with limited competition, complex formulation characteristics, or high regulatory barriers to entry. Its portfolio encompasses multiple therapeutic categories, including central nervous system agents such as melatonin oral solutions and tablets (Mellozzan) indicated for pediatric insomnia and sleep disorders; cardiovascular and metabolic therapeutics, including potassium chloride formulations (Kaliumklorid EQL Pharma) and lipid regulators; anti-infectives, systemic antibiotics, and hospital injectables; analgesics and anti-inflammatory drugs; gastrointestinal treatments; and essential vitamins and supplements, including colecalciferol. EQL Pharma provides pharmaceutical products across various delivery forms, such as oral tablets, capsules, liquid solutions, and sterile intravenous injectables, serving public healthcare authorities, hospitals, retail pharmacy chains, and pharmaceutical wholesalers. Geographically, the company conducts direct commercial operations primarily across the Nordic region, including Sweden, Denmark, Norway, and Finland, while extending its commercial reach across broader Europe and international markets through direct sales and out-licensing distribution partnerships. In recent developments, EQL Pharma has accelerated its European expansion by securing strategic out-licensing and commercialization partnerships for its proprietary products, including Mellozzan; expanded its commercial pipeline through new in-licensing agreements with international contract development and manufacturing organizations; secured multiple national and regional public hospital tender awards across Northern Europe; and broadened its portfolio with new market authorizations and product launches in niche hospital injectables and specialty oral prescription drugs. Founded in 2006, EQL Pharma AB is headquartered in Lund, Sweden.